'High-priced Poker Game'

Apr 20, 2012

GlaxoSmithKline has made a $2.6 billion unsolicited offer to take over Human Genome Sciences, reports Brett Chase at Miyanville. But not only has Human Genome rejected Glaxo's offer, it put itself up for sale to the highest bidder, saying Glaxo's offer of $13 a share is too low and doesn't reflect the potential value of the company.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Breaking News

The Scan

Areas of Limited Testing

The Wall Street Journal reports on gaps in COVID-19 testing affecting less affluent urban areas and rural locations.

Clouded 'Crystal Ball'

According to NBC News, new SARS-CoV-2 variants are making it harder for researchers to model the course of the pandemic.

Million a Day

The New York Times reports that experts say President Joe Biden's goal of vaccinating 1 million people a day in the US in the next 100 days is too low a bar.

Science Papers Trace Drivers of Metastasis; Genetic Analysis of Stone, Bronze Age Eastern Europeans

In Science this week: single-cell lineage tracing technique applied to study lung cancer metastasis, and more.

Menu